Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

This study has been terminated.
(Enrollment stopped for safety issues)
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00412750
First received: December 15, 2006
Last updated: June 14, 2011
Last verified: June 2011
  Purpose

To evaluate the combination of telbivudine 600 mg orally (PO) once daily and peginterferon alpha-2a 180 ug subcutaneous (sq) injection weekly for antiviral efficacy in comparison to peginterferon alpha-2a monotherapy.


Condition Intervention Phase
Hepatitis B
Drug: Telbivudine (LdT)
Drug: peginterferon alpha-2a
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq 180 µg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Treatment naïve Patients With HBeAg-positive CHB.

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage of Participants Who Achieved HBV DNA Non-detectability With Peginterferon Alpha-2a Plus Telbivudine Combination Therapy Versus Peginterferon Alpha-2a Monotherapy [ Time Frame: At week 52 ] [ Designated as safety issue: No ]
    The original primary efficacy variable was the percentage of patients achieving HBV DNA non-detectability utilizing polymerase chain reaction (PCR) (threshold for detection 300 copies/mL); however, this analysis was not performed due to premature study termination.

  • Percentage of Participants With HBV DNA Non-detectability and Alanine Aminotransferase (ALT) Normalization at Week 12 and Week 24 in Participants With HBeAg-positive Chronic Hepatitis B (CHB) [ Time Frame: Weeks 12 and 24 ] [ Designated as safety issue: No ]
    The percentage of participants who achieved HBV DNA non-detectability using the COBAS Amplicor HBV Monitor assay utilizing polymerase chain reaction (PCR) (threshold for detection 300 copies/mL) and Alanine aminotransferase (ALT) normalization defined as ALT within normal limits on two successive visits for a patient with an elevated ALT (>1.0 x upper limit normal) at baseline summarized at Weeks 12 and 24.


Secondary Outcome Measures:
  • Change From Baseline in HBV DNA Concentration [ Time Frame: Weeks 12 and 24 ] [ Designated as safety issue: No ]
    The change from baseline in HBV DNA concentration at Weeks 12 and 24 was analyzed using an analysis of covariance (ANCOVA) model with baseline HBV DNA concentration (log10 copies/ml) as a covariate, treatment and country as factors.

  • Percentage of Participants Who Experienced Virologic Breakthrough at Weeks 48 and 52 [ Time Frame: Weeks 48 and 52 ] [ Designated as safety issue: No ]
    The percentage of participants with Virologic breakthrough at Week 48 and 52 by treatment. For the subgroup of patients on treatment who achieve HBV DNA >= 1 log10 copies/mL reduction from baseline on 2 consecutive visits, Virologic Breakthrough is defined as HBV DNA >= 1 log10 copies/mL from nadir on two consecutive visits.

  • Percentage of Participants With Hepatitis B 'e' Antigen (HBeAg) Loss and HBeAg Seroconversion [ Time Frame: Weeks 18, 24, 48, 52 and Treatment completion (TC) ] [ Designated as safety issue: No ]
    HBeAg loss is defined as the loss of detectable serum HBeAg in a patient who was HBeAg positive at baseline. HBeAg seroconversion is defined as HBeAg loss with detectable Hepatitis B 'e' antibody (HBeAb). The efficacy was assessed for 18 weeks, 24 weeks, 48 weeks, 52 weeks and on treatment completion (TC).

  • Percentage of Participants Who Achieved HBV DNA Non-detectability With Telbivudine Monotherapy Versus Peginterferon Alpha-2a Monotherapy [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    Antiviral efficacy was assessed by percentage of patients achieving HBV DNA non-detectability assay utilizing polymerase chain reaction (PCR) (threshold for detection 300 copies/mL); however, this analysis was not performed due to premature study termination.

  • Percentage of Participants Who Achieved HBV DNA Non-detectability With Peginterferon Alpha-2a Plus Telbivudine Combination Therapy Versus Telbivudine Monotherapy [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    Antiviral efficacy was assessed by percentage of patients achieving HBV DNA non-detectability assay utilizing polymerase chain reaction (PCR) (threshold for detection 300 copies/mL); however, this analysis was not performed due to premature study termination.


Enrollment: 159
Study Start Date: December 2006
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LdT+ PEG-INF
Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.
Drug: Telbivudine (LdT)
600 mg orally once daily for 104 weeks.
Other Name: Sebivo
Drug: peginterferon alpha-2a
180 μg subcutaneous injection once a week for 52 weeks.
Other Name: Pegasys
Experimental: LdT Monotherapy
Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.
Drug: Telbivudine (LdT)
600 mg orally once daily for 104 weeks.
Other Name: Sebivo
Active Comparator: PEG-INF Monotherapy
Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.
Drug: peginterferon alpha-2a
180 μg subcutaneous injection once a week for 52 weeks.
Other Name: Pegasys

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Documented Chronic hepatitis B (CHB) defined by all of the following:

  • Clinical history compatible with CHB
  • Detectable serum Hepatitis B Surface Antigen (HBsAg) at the Screening visit and at least 6 months prior
  • HBeAg-positive at the Screening visit
  • Hepatitis B 'e' Antibody (HBeAb)-negative at the Screening visit
  • History of evidence of chronic liver inflammation,
  • Elevated serum Alanine aminotransferase (ALT) level (1.3 - 10 x upper limit of normal (ULN)) at the Screening visit
  • Serum HBV DNA level ≥ 6 log10 copies/mL,
  • Chronic liver inflammation on previous liver biopsy within the previous 24 months.

Exclusion Criteria:

  • Co-infection with Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), or Human Immunodeficiency Virus (HIV).
  • Has any of the following drug therapy:

    • Previously been treated in a trial with telbivudine
    • Received nucleoside or nucleotide therapy whether approved or investigational
    • Received any immunomodulatory treatment in the 12 months before Screening for this study.
    • Has a medical condition that required prolonged or frequent use of systemic acyclovir or famciclovir.
    • Has a medical condition that requires frequent or prolonged use of systemic corticosteroids although inhaled or intra-articular corticosteroids are allowed.
    • Has a medical condition requiring the chronic or prolonged use of potentially hepatotoxic drugs or nephrotoxic drugs.
    • Is currently abusing alcohol or illicit drugs or has a history of alcohol abuse illicit substance abuse within the preceding two years.
    • Uses other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
    • Is currently receiving methadone.
  • Patient has any of the following:

    • History of or clinical signs/symptoms of hepatic decompensation such as ascites, esophageal variceal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis.
    • History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. Patients with previous findings suggestive of possible HCC should have the disease ruled out prior to entrance into the study.
    • One or more additional known primary or secondary causes of liver disease other than hepatitis B, including steatohepatitis.
    • History of clinical and laboratory evidence of chronic pancreatitis, or demonstrates a clinical and laboratory course consistent with current pancreatitis.
  • Has laboratory values during screening visit not within normal limits.
  • Is pregnant or breastfeeding.
  • Is a women of child-bearing potential that is unwilling to practice birth control.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00412750

Locations
United States, California
Novartis
San Francisco, California, United States, 94115
Sponsors and Collaborators
Novartis
  More Information

No publications provided

Responsible Party: novartis, novatis
ClinicalTrials.gov Identifier: NCT00412750     History of Changes
Obsolete Identifiers: NCT00376389
Other Study ID Numbers: CLDT600A2406
Study First Received: December 15, 2006
Results First Received: December 2, 2010
Last Updated: June 14, 2011
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Spain: Ministry of Health and Consumption
Switzerland: Federal Office of Public Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Israel: Ministry of Health
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Taiwan: National Bureau of Controlled Drugs
Singapore: Health Sciences Authority
New Zealand: Health and Disability Ethics Committees
Hong Kong: Department of Health

Keywords provided by Novartis:
hepatitis B
hepatitis B Virus (HBV)
chronic hepatitis B
telbivudine
peginterferon

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis, Chronic
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Peginterferon alfa-2a
Interferon-alpha
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 24, 2014